These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1133 related items for PubMed ID: 20171423

  • 1. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [Abstract] [Full Text] [Related]

  • 2. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers.
    Kim TE, Kim BH, Kim J, Kim KP, Yi S, Shin HS, Lee YO, Lee KH, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896
    [Abstract] [Full Text] [Related]

  • 4. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T, Blight AR, Henney HR.
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [Abstract] [Full Text] [Related]

  • 5. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH, Shin KH, Kim J, Lim KS, Kim KP, Kim JR, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [Abstract] [Full Text] [Related]

  • 7. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker.
    Falcão A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P.
    Biopharm Drug Dispos; 2007 Jul; 28(5):249-56. PubMed ID: 17443646
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T, Henney HR.
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.
    Nunes T, Sicard E, Almeida L, Falcão A, Rocha JF, Brunet JS, Lefebvre M, Soares-da-Silva P.
    Curr Med Res Opin; 2010 Jun; 26(6):1355-62. PubMed ID: 20377319
    [Abstract] [Full Text] [Related]

  • 10. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
    Vaz da Silva M, Costa R, Soares E, Maia J, Falcão A, Almeida L, Soares da Silva P.
    Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
    [Abstract] [Full Text] [Related]

  • 11. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K.
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK, Cheng G, Tang J, Song J, Peng WX.
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [Abstract] [Full Text] [Related]

  • 13. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD, Kang W, Lee HW, Park DJ, Ahn JH, Kim MJ, Kim EY, Kim SW, Nam HS, Na HJ, Yoon YR.
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [Abstract] [Full Text] [Related]

  • 14. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA.
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [Abstract] [Full Text] [Related]

  • 16. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.
    Am J Ther; 2009 Oct; 16(3):215-23. PubMed ID: 19454860
    [Abstract] [Full Text] [Related]

  • 17. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ.
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [Abstract] [Full Text] [Related]

  • 18. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.
    Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
    [Abstract] [Full Text] [Related]

  • 19. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D, Speed J, Medve R, Andrews JS.
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [Abstract] [Full Text] [Related]

  • 20. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A.
    Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.